濮阳东方医院割包皮手术手术贵吗濮阳东方男科评价非常好,濮阳东方男科治病好不好,濮阳市东方医院附近站牌,濮阳东方男科医院医生怎么样,濮阳东方医院看妇科病评价好很不错,濮阳东方男科医院坐公交路线,濮阳东方医院男科割包皮好不好

WASHINGTON, June 6 (Xinhua) -- A new University of Missouri study shows that the exposure to the controversial chemical Bisphenol A (BPA) through diet has been underestimated by previous lab tests.The findings were published on Monday in Environmental Health Perspectives.In the study, researchers compared BPA concentrations in mice that were given a steady diet supplemented with BPA throughout the day, compared to the more common lab method of single exposure, and found an increased absorption and accumulation of BPA in the blood of the mice.The authors continuously exposed the mice to BPA through their feed, which is considered the primary route of exposure to this chemical in animals and humans. In previous studies examining the effects of BPA, mice were exposed to BPA only through a one-time administration.Following the exposure through the diet, a significantly greater increase in the active form of BPA, which is the greatest threat as it is the form that can bind to sex steroid receptors and exert adverse effects, was absorbed and accumulated in the animals."People are primarily and unknowingly exposed to BPA through the diet because of the various plastic and paper containers used to store our food are formulated with BPA," said Cheryl Rosenfeld, associate professor in biomedical sciences and corresponding lead author. "We know that the active form of BPA binds to our steroid receptors, meaning it can affect estrogen, thyroid and testosterone function. It might also cause genetic mutations. Thus, this chemical can hinder our ability to reproduce and possibly cause behavioral abnormalities that we are just beginning to understand."The study notes that more than eight billion pounds of BPA are produced every year, and more than 90 percent of people in the United States have measurable amounts of BPA in their bodies."When BPA is taken through the food, the active form may remain in the body for a longer period of time than when it is provided through a single treatment, which does not reflect the continuous exposure that occurs in animal and human populations," said Rosenfeld. "We need to study this further to determine where the ingested BPA becomes concentrated and subsequently released back into the bloodstream to be distributed throughout the body."

BEIJING, Sept. 27 (Xinhuanet) -- People having a dog is way healthier than those don't, both physically and mentally, media reports said Tuesday.People owning dogs are more likely to take exercises than those having none, according to a recent poll of Mars Petcare, a pet food company.Two thirds of the walks dog owners take each week are attributed to their dogs, according to the poll, in which over 1,000 adults were surveyed.The survey also showed that 44 percent of dog owners over 65 years old make exercises because of their dogs.Dogs are a great motivator for doing exercises, said Dr. Sandra McCune, an animal behaviorist and also co-author of the book, "The Health Benefits of Dog Walking for People and Pets".

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, July 17 (Xinhua) -- China's land prices in 105 cities rose 1.87 percent on average in the second quarter over the first, but the rate of growth slowed, the China Urban Land Price Dynamic Monitor, a land price information provider, announced Sunday. < In the second quarter, land price for business properties averaged 5,506 yuan (about 847 U.S. dollars) per square meter, up 2.77 percent from the previous quarter. The growth rate slowed by 0.56 percentage points.Land price for residential properties averaged 4,443 yuan per square meter, up 2.17 percent. The growth slowed by 0.27 percentage points. The price for industrial uses, meanwhile, was up 1.13 percent to reach 645 yuan per square meter. The growth fell 0.3 percentage points.The country's three most prosperous regions, the Yangtze River Delta Region, Pearl River (Zhujiang) Delta Region, and the Bohai Rim, all reported slower land price growth in the second quarter.

WASHINGTON, June 14 (Xinhua) -- Eating a low-carbohydrate, high- protein diet may reduce the risk of cancer and slow the growth of tumors already present, according to a study published Tuesday in Cancer Research, a journal of the American Association for Cancer Research.The study was conducted in mice, but the scientists involved agree that the strong biological findings are definitive enough that an effect in humans can be considered."This shows that something as simple as a change in diet can have an impact on cancer risk," said lead researcher Gerald Krystal, a scientist at the British Columbia Cancer Research Center.Krystal and his colleagues implanted various strains of mice with human tumor cells or with mouse tumor cells and assigned them to one of two diets. The first diet, a typical Western diet, contained about 55 percent carbohydrate, 23 percent protein and 22 percent fat. The second, which is somewhat like a South Beach diet but higher in protein, contained 15 percent carbohydrate, 58 percent protein and 26 percent fat. They found that the tumor cells grew consistently slower on the second diet.As well, mice genetically predisposed to breast cancer were put on these two diets and almost half of them on the Western diet developed breast cancer within their first year of life while none on the low-carbohydrate, high-protein diet did. Interestingly, only one on the Western diet reached a normal life span ( approximately 2 years), with 70 percent of them dying from cancer while only 30 percent of those on the low-carbohydrate diet developed cancer and more than half these mice reached or exceeded their normal life span.Krystal and colleagues also tested the effect of an mTOR inhibitor, which inhibits cell growth, and a COX-2 inhibitor, which reduces inflammation, on tumor development, and found these agents had an additive effect in the mice fed the low-carbohydrate, high-protein diet.When asked to speculate on the biological mechanism, Krystal said that tumor cells, unlike normal cells, need significantly more glucose to grow and thrive. Restricting carbohydrate intake can significantly limit blood glucose and insulin, a hormone that has been shown in many independent studies to promote tumor growth in both humans and mice.Furthermore, a low-carbohydrate, high-protein diet has the potential to both boost the ability of the immune system to kill cancer cells and prevent obesity, which leads to chronic inflammation and cancer.